Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
We’re looking forward to the launch of the WHO report on epilepsy today @ 12:00 #IEC2019 #WHO. We agree, it is very important that epilepsy be recognized as a public health priority. #treatment_gap https://t.co/RrLVpUOavH
— UCB News (@ucb_news) 24.06.2019 -
#myastheniagravis is such an unpredictable and fluctuating disease. Our infographic gives you the low-down. ❄️ #mygroove #snowflakedisease https://t.co/bOyLHzX5eH
— UCB News (@ucb_news) 24.06.2019 -
UCB is very proud to sponsor The Michael Prize, recognizing outstanding contributions to epilepsy scientific and clinical research. Congratulations to Dr. Birgit Frauscher and Dr. Stéphanie Baulac who, at #IEC2019 have been announced as this year’s worthy
— UCB News (@ucb_news) 24.06.2019
